Waters K A, Everett F M, Bruderer J W, Sullivan C E
David Read Sleep Disorders Unit, University of Syndey, Australia.
Am J Respir Crit Care Med. 1995 Aug;152(2):780-5. doi: 10.1164/ajrccm.152.2.7633742.
This is a retrospective review of children 15 years of age or younger, who underwent overnight sleep studies between 1980 and 1993. All were diagnosed and treated for obstructive sleep apnea (OSA). Overnight studies were performed for OSA in 413 children. One hundred seventy-five (42.4%) children were treated with adenotonsillectomy and 80 (19.4%) with nasal mask continuous positive airway pressure (nCPAP). The proportion of male children was greater than expected in both the entire study group (69%, p < 0.001) and in those treated with nCPAP for OSA (71% p < 0.001). There was no significant difference between the mean age of the children treated with nCPAP (5.7 +/- 0.5 yr) and the entire group studied (5.04 +/- 0.21 yr). A greater proportion of the children who received nCPAP therapy had a congenital syndrome or malformation than in the group with OSA as a whole; 27.7% of children assessed for OSA were affected, and 53% of those children with OSA who received treatment with nCPAP (p < 0.001). Therapy with nCPAP (mean duration 15 +/- 3 mo, mean pressure 7.9 cm H2O) eliminated the signs of OSA in 72 children (90%). Respiratory disturbance index fell from a mean of 27.3 +/- 20.2 to 2.55 +/- 2.74 (p < 0.001). Eight of 32 children who underwent pressure determination studies could not tolerate nCPAP above an upper limit because of hypoventilation or frequent central apneas. Nevertheless, we conclude that nCPAP is an effective and generally well-tolerated therapy for treatment of OSA in infants and children.
这是一项对15岁及以下儿童的回顾性研究,这些儿童在1980年至1993年间接受了夜间睡眠研究。所有儿童均被诊断为阻塞性睡眠呼吸暂停(OSA)并接受了治疗。413名儿童因OSA接受了夜间研究。175名(42.4%)儿童接受了腺样体扁桃体切除术治疗,80名(19.4%)儿童接受了鼻罩持续气道正压通气(nCPAP)治疗。在整个研究组(69%,p<0.001)以及接受nCPAP治疗OSA的儿童中(71%,p<0.001),男性儿童的比例均高于预期。接受nCPAP治疗的儿童平均年龄(5.7±0.5岁)与整个研究组(5.04±0.21岁)之间无显著差异。接受nCPAP治疗的儿童中,患有先天性综合征或畸形的比例高于整个OSA组;评估为OSA的儿童中有27.7%受到影响,接受nCPAP治疗的OSA儿童中有53%受到影响(p<0.001)。nCPAP治疗(平均持续时间15±3个月,平均压力7.9 cm H2O)使72名儿童(90%)的OSA体征消失。呼吸紊乱指数从平均27.3±20.2降至2.55±2.74(p<0.001)。在32名接受压力测定研究的儿童中,有8名由于通气不足或频繁的中枢性呼吸暂停而无法耐受高于上限的nCPAP。然而,我们得出结论,nCPAP是治疗婴幼儿OSA的一种有效且普遍耐受性良好的疗法。